WHO ICTRP trial
Phase Ib study of PDR001 in combination with regorafenib in adult patients with…
NL-OMON45600 · Overview of Medical Research in the Netherlands (NL-OMON)
Key facts
| Trial ID | NL-OMON45600 |
|---|---|
| Public title | Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer |
| Scientific title | Phase Ib study of PDR001 in combination with regorafenib in adult patients with previously treated metastatic microsatellite stable (MSS) colorectal cancer - PDR001 and regorafenib in MSS colorectal cancer |
| Primary sponsor | Novartis |
| Registry | Overview of Medical Research in the Netherlands (NL-OMON) |
| Study type | Interventional |
| Countries | Belgium;Canada;France;Germany;Hong Kong;Israel;Italy;Japan;Korea (the Republic of);Lebanon;Netherlands;Spain;Togo;United States of America |
| Conditions | Colorectal carcinoma;10017991;Colorectal carcinoma |
| Interventions | Treatment with PDR001 in combination with regorafenib. PDR001 (intraveneus) - 400mg per 4 weken Regorafenib (oraal): startdosering 120mg/ dag. Volgende dosisnieveau: 160mg/dag. ;Colorectal carcinoma;PDR001;Phase Ib;regorafenib |
| Registration date | Jun 28, 2017 |
| Target size | 6 |
| Secondary IDs | 2017-000466-30;NCT03081494;NL61135.058.17 |
| Registry page | onderzoekmetmensen.nl |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: